TrialAnnals of the rheumatic diseases2022

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis.

David Jayne et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.